Bausch Health Companies Inc. (BHC) Stock Price & Analysis
Bausch Health Companies Inc. (BHC) closed at USD 6.49 on Thursday, October 22, 2026, up 0.62% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 6.45; the Oct 22, 2026 session ranged USD 6.41–6.51 on volume of 1,196,577 shares. Market capitalization is $2.43B, with a 52-week range of USD 4.33–8 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 10:07 UTC.
Also available as compact Markdown for AI agents: nexqual.com/BHC.md
Key facts (BHC)
- Last four reported quarters (through Jun 30, 2026): revenue $10.9B, net income -$1.10B (-10.1% margin), free cash flow $1.43B (SEC filings).
- Insider open-market sales, last ~7 months: 2 Form 4 filings, $392K; 0 not under a Rule 10b5-1 plan ($0K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Hold (mean 3.00 on a 1–5 scale) (7 analysts), mean target USD 7.5 (range 6.5–9).
- Total return with dividends: 1Y +1.7% vs S&P 500 +14.9%; 5Y -77.4% vs S&P 500 +80.3%.
- Next earnings: 2026-10-28, EPS estimate USD 1.24, revenue estimate $2.75B.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (BHC)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $8.43B | $8.12B | $8.76B | $9.63B | $10.3B | $10.9B |
| Operating income | $450M | $454M | $963M | $1.55B | $1.81B | $883M |
| Net income | -$948M | -$225M | -$592M | -$46.0M | $157M | -$1.10B |
| EPS (diluted) | -$2.64 | -$0.62 | -$1.62 | -$0.13 | $0.42 | — |
| Free cash flow | $1.16B | -$946M | $817M | $1.26B | $1.00B | $1.43B |
| Operating margin | 5.3% | 5.6% | 11.0% | 16.1% | 17.7% | 8.1% |
| Net margin | -11.2% | -2.8% | -6.8% | -0.5% | 1.5% | -10.1% |
| Revenue growth | +5.1% | -3.7% | +7.8% | +9.9% | +6.7% | — |
| Cash + short-term investments | $582M | $564M | $947M | $1.18B | $1.31B | — |
| Total debt | $22.7B | $20.8B | $22.4B | $21.6B | $20.8B | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (BHC)
P/S 0.2x · EV/EBITDA 10.4x · EV/Sales 2.0x · P/FCF 1.7x · FCF yield 58.96% · Earnings yield -45.24% · Net debt $18.9B · EV $21.3B
P/E at fiscal year-ends: Dec 2025 16.6x.
Insider sales (SEC Form 4, open-market, last ~7 months) (BHC)
2 of 2 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-08-19 | Lenar Aimee J. | President, US Pharma | 36,827 | $259K | 9.9% | Yes (adopted May 21, 2026) | Too little history (no open-market trades in 2023–2025) |
| 2026-05-19 | Lee Frank D. | Director | 24,456 | $133K | 33.1% | Yes | Too little history (no open-market trades in 2023 or 2024) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (BHC)
Consensus Hold (mean 3.00 on a 1–5 scale), 7 analysts; mean target USD 7.5 (low 6.5, high 9).
Total return (dividends reinvested) (BHC)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +1.7% | -77.4% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +1.7% | -25.7% |
| Volatility (annualized) | 54.4% | 71.3% |
| Max drawdown | -43.9% (Jan 2026→Jul 2026) | -85.0% (Oct 2021→Apr 2025) |
BHC revenue by business segment (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Bausch + Lomb | $1.39B | 48.9% | +9.1% |
| Salix | $758.0M | 26.6% | +20.9% |
| International | $305.0M | 10.7% | +9.7% |
| Diversified | $219.0M | 7.7% | +0.0% |
| Solta Medical | $176.0M | 6.2% | +37.5% |
| Total revenue | $2.85B | 100% | — |
BHC revenue by product line (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Product sales | $2.83B | 99.1% | +12.8% |
| Other revenues | $27.0M | 0.9% | +3.8% |
| Total revenue | $2.85B | 100% | — |
BHC revenue by region (fiscal year ended Dec 31, 2025)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| United Statesand Puerto Rico | $6.14B | 59.8% | +6.4% |
| Other Countries | $1.15B | 11.2% | +6.5% |
| China | $493.0M | 4.8% | -0.6% |
| CANADA | $417.0M | 4.1% | +3.7% |
| Poland | $382.0M | 3.7% | +9.1% |
| Mexico | $278.0M | 2.7% | -11.7% |
| France | $249.0M | 2.4% | +8.3% |
| South Korea | $234.0M | 2.3% | +60.3% |
| Russia | $198.0M | 1.9% | +23.0% |
| Japan | $192.0M | 1.9% | +2.1% |
| Germany | $176.0M | 1.7% | +10.7% |
| United Kingdom | $141.0M | 1.4% | +4.4% |
| Spain | $109.0M | 1.1% | +10.1% |
| Italy | $106.0M | 1.0% | +12.8% |
| Total revenue | $10.27B | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
BHC suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Supplier | Lundbeck | “In the U.S., Xenazine® is distributed for us by Lundbeck LLC under an exclusive marketing, distribution and supply agreement.” |
| Customer | McKesson (MCK) | “The Company has Distribution Services Agreements ("DSAs") with several large wholesale customers such as McKesson Corporation, Cencora Inc., Cardinal Health, Inc. and McKesson Specialty.” |
| Customer | Cencora (COR) | “The Company has Distribution Services Agreements ("DSAs") with several large wholesale customers such as McKesson Corporation, Cencora Inc., Cardinal Health, Inc. and McKesson Specialty.” |
| Customer | Cardinal Health (CAH) | “The Company has Distribution Services Agreements ("DSAs") with several large wholesale customers such as McKesson Corporation, Cencora Inc., Cardinal Health, Inc. and McKesson Specialty.” |
| Related party | Lomb | “Although all transactions with related parties will be approved by independent members of our Board of Directors that may meet in the absence of senior executive officers or non-independent directors, the ownership of Bausch + Lomb equity or service to Bausch + Lomb may create the appearance of conflicts of interest when the Bausch + Lomb-affiliated directors and officers are faced with decisions that could have d…” |
Quoted from the company's 10-K filed Feb 19, 2026.
Companies that name BHC in their SEC reports
| Relationship to BHC | Company | Filing | Sentence |
|---|---|---|---|
| partner | HYPERION DEFI, INC. (HYPD) | 10-K Mar 30, 2026 | “During 2020, the Company entered into a license agreement, or the Arctic Vision License Agreement, with Arctic Vision (Hong Kong) Limited, or Arctic Vision, and a license agreement, or the Bausch License Agreement, with Bausch Health Companies, Inc., or Bausch + Lomb.” |
| partner | Xenon Pharmaceuticals Inc. (XENE) | 10-K Feb 26, 2026 | “In April 2017, we entered into an asset purchase agreement with 1st Order Pharmaceuticals, Inc., or 1st Order, pursuant to which we acquired all rights with respect to azetukalner (previously known as 1OP2198 and XEN1101). 1st Order previously acquired 1OP2198 from Valeant Pharmaceuticals Luxembourg S.a.r.l., an indirect subsidiary of Bausch Health Companies Inc., together with Valeant Pharmaceuticals Ireland Limi…” |
| partner | Lantheus Holdings, Inc. (LNTH) | 10-K Feb 26, 2026 | “In 2011 Progenics licensed methylnaltrexone ("MNTX") and products containing MNTX, including both approved forms of RELISTOR, to Salix Pharmaceuticals, Inc., an affiliate of Bausch Health Companies, Inc. ("Bausch") and on August 2, 2023, we sold the right to the RELISTOR net sales royalties under that license agreement and retained the rights to future sales-based milestone payments.” |
| related | Bausch & Lomb Corp (BLCO) | 10-K Feb 18, 2026 | “Although all transactions with related parties will be approved by independent members of our Board of Directors that may meet in the absence of senior executive officers or non-independent directors, the ownership of BHC equity or service to BHC may create the appearance of conflicts of interest when the BHC-affiliated directors and officers are faced with decisions that could have different implications for BHC …” |
BHC customer concentration
In the period ended Dec 31, 2025, 3 direct customers each accounted for at least 10% (18%, 16%, 14%) of revenue, per the company's 10-K filed Feb 19, 2026. The company does not name them.
BHC company outlook (results filed Jul 29, 2026)
- “The Company updated its Consolidated full-year Revenue and Adjusted EBITDA (non-GAAP) 1 guidance for 2026.”
- “Bausch Health (excluding Bausch + Lomb) is raising its full year Revenue, Adjusted EBITDA (non-GAAP) 1 , and Adjusted Cash Flows from Operations (non-GAAP) 1 guidance, which includes the currently estimated impact of applicable tariffs for the calendar year as of the date of this release.”
- “Current Guidance (as of July 29, 2026) BHC BHC (excl.”
- “Prior Year 8% - 11% Adjusted Cash Flows from Operations 1 (in Billions) $1.400 - $1.475 Other than with respect to GAAP revenues, the Company only provides guidance on a non-GAAP basis.”
Quoted word-for-word from the SEC 8-K results press release.
BHC analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $1.24 | $1.28 | -3.0% | $2.75B | 6 |
| Next quarter (ends Dec 2026) | $1.29 | $1.36 | -5.4% | $2.79B | 6 |
| Current fiscal year (ends Dec 2026) | $4.52 | $4.42 | +2.3% | $10.92B | 6 |
| Next fiscal year (ends Dec 2027) | $4.29 | $4.22 | +1.8% | $10.94B | 6 |
Key Statistics (as of October 23, 2026 at 10:07 UTC)
| Price | USD 6.49 |
|---|---|
| Change | ▲ 0.62% (up) |
| Previous Close | USD 6.45 |
| Open | USD 6.43 |
| Day Range | USD 6.41 – 6.51 |
| 52-Week Range | USD 4.33 – 8 |
| Volume | 1,196,577 shares |
| Market Cap | $2.43B |
| Exchange | NYQ |
Technical Analysis (BHC)
Nexqual's technical model rates BHC "BUY" based on 5 bullish and 1 bearish signals across 127 daily candles, as of October 23, 2026 at 10:07 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 61.51 (neutral) |
| vs SMA50 | Above (USD 6.17) |
| MACD | 0.12 (positive) |
Analyst Ratings (BHC)
Wall Street analysts rate BHC "Hold" based on 7 analysts, with a mean price target of USD 7.5 (range USD 6.5–9), per Nexqual as of October 23, 2026 at 10:07 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 7 |
| Mean Target | USD 7.5 |
| High Target | USD 9 |
| Low Target | USD 6.5 |
| Buy / Hold / Sell | 0 / 7 / 0 |
Earnings (BHC)
| Next Earnings Date | 2026-10-28 |
|---|---|
| EPS Estimate | USD 1.24 |
| Revenue Estimate | $2.75B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 1.26 vs est 1.01 ▲ beat |
| 2026-03-31 | USD 0.78 vs est 0.69 ▲ beat |
| 2025-12-31 | USD 1.1 vs est 1.26 ▼ miss |
| 2025-09-30 | USD 1.16 vs est 1.06 ▲ beat |
Source: Nexqual, October 23, 2026 at 10:07 UTC.
Financials & Fundamentals (BHC)
| Total Revenue | $10.85B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +12.70% |
| Gross Margin | +71.82% |
| Operating Margin | +27.17% |
| Profit Margin | -10.12% |
| Current Ratio | 1.44 |
| Total Cash | $1.82B |
| Total Debt | $20.78B |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | $1.43B (13.2% of revenue) |
Source: Nexqual, October 23, 2026 at 10:07 UTC.
Financial Health Score (BHC)
Nexqual rates Bausch Health Companies Inc.'s overall financial health "Solid" across five dimensions, as of October 23, 2026 at 10:07 UTC.
| Growth | Solid — Revenue +7% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 72%, operating 27% (last 12 months) |
| Balance Sheet | Mixed — $1.82B cash and investments vs $20.7B debt (Jun 2026, SEC) |
| Cash Flow | Solid — FCF $1.43B (last 4 quarters to Jun 2026, SEC), 13% margin |
| Efficiency | Mixed — No data |
Ownership (BHC)
| Insider Ownership | +11.12% |
|---|---|
| Institutional Ownership | +65.00% |
| Shares Outstanding | 373.99M |
| Float | 260.57M |
| Short % of Float | +2.81% |
Source: Nexqual, October 23, 2026 at 10:07 UTC.
Leadership (BHC)
Bausch Health Companies Inc. is led by Thomas J. Appio, CEO & Director, per Nexqual as of October 23, 2026 at 10:07 UTC.
| CEO & Director | Thomas J. Appio |
|---|---|
| Executive VP & CFO | Jean-Jacques Charhon |
| President of US Pharma | Aimee J. Lenar |
| Executive VP & COO | Mirza Dautbegovic |
| Senior Vice President of Europe & Canada | Cees Heiman |
Major Backers & Investors (BHC)
Notable institutional backers of Bausch Health Companies Inc. include PAULSON & CO. INC., Goldentree Asset Management LP, Royal Bank of Canada, according to Nexqual as of October 23, 2026 at 10:07 UTC.
Active Investors
| Investor | Stake |
|---|---|
| PAULSON & CO. INC. | 19.57% |
| Goldentree Asset Management LP | 9.26% |
| Royal Bank of Canada | 2.89% |
| Healthcare of Ontario Pension Plan Trust Fund | 2.14% |
| Goldman Sachs | 1.66% |
| MFN Partners Management, LP | 1.6% |
| SG Americas Securities, LLC | 1.48% |
| Acadian Asset Management. LLC | 1.46% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 1.99% |
Source: Nexqual, October 23, 2026 at 10:07 UTC.
From Bausch Health Companies Inc.'s Latest SEC 10-K Filing (filed 2026-02-19)
Key Strengths & Strategy (as disclosed to the SEC)
- We have implemented initiatives, including increasing our marketing investment in Xifaxan®, to seek to further capitalize on the value of the infrastructure we have built around these products to extend our market share.
- The Company utilizes the Generics business to extend the long-term cash flows from a number of assets that are expected to decline over time due to their loss of exclusivity, by launching and selling generic versions of certain branded assets including authorized generics ("AG"). •Arestin® (minocycline hydrochloride) is the only FDA approved subgingival sustained-release antibiotic on the market.
- For example, in the European Economic Area (the "EEA"), the collection and use of personal data, including clinical trial data, is governed by the provisions of the General Data Protection Regulation (the "GDPR").
- We rely on a combination of contractual provisions, confidentiality policies and procedures and patent, trademark, copyright and trade secrecy laws to protect the proprietary aspects of our technology and business.
Legal & Regulatory Risks (Item 1A, quoted)
- We are the subject of and may become subject to additional legal and governmental proceedings, which have had and could continue to have a material adverse effect on our reputation and business, and could result in additional claims and material liabilities.
- We may be involved in additional litigation in the future.
- We depend on third parties to meet their contractual, legal, regulatory, and other obligations, and actions by these third parties could have a material adverse effect on our business.
- Our marketing, promotional and business practices, as well as the manner in which sales forces interact with purchasers, prescribers and patients, are subject to extensive regulation and any material failure to comply could result in significant sanctions against us.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SUPN | Supernus Pharmaceuticals, Inc. | USD 42.07 | ▲ 2.09% |
| HCM | HUTCHMED (China) Limited | USD 14.28 | ▼ 0.63% |
| LQDA | Liquidia Corporation | USD 39.69 | ▲ 2.14% |
| AMLX | Amylyx Pharmaceuticals, Inc. | USD 28.57 | ▼ 1.58% |
| INDV | Indivior Pharmaceuticals, Inc. | USD 35.33 | ▲ 1.55% |
| RGC | Regencell Bioscience Holdings L | USD 9.81 | ▼ 9.17% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 10:07 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt